Noxopharm
Follow
Get notifications in MyBN when activity occurs.
Industry Lists
Public Companies - non WANoxopharm Limited (NOX) is a clinical-stage Australian drug development company with offices in Sydney and New York.
The company has a primary focus on the development of Veyonda and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.
Contact Details
Suite 3, Level 4, 828 Pacific Hwy, GORDON NSW 2072
02 9144 2223
Lists and Charts
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 842nd |  | Noxopharm | $6.0m |
| 993rd | | Amplia Therapeutics | $1.2m |
| 995th | | Kneomedia | $1.2m |
| 997th | | Benjamin Hornigold | $1.2m |
| 998th | | Global Masters Fund | $1.2m |
1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 248th | Global Masters Fund | 42% | 9% |
| 531st | Benjamin Hornigold | 9% | -19% |
| 906th | Amplia Therapeutics | -12% | -8% |
| 954th | Noxopharm | -15% | -27% |
| 1786th | Kneomedia | -74% | -34% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Company Activity
| NEW ROLE: Gisela Mautner, Chief Executive, Managing Director | 14 Feb 2022 |
| NEW ROLE: Greg Van Wyk, | 24 Nov 2020 |
| NEW ROLE: Fred Bart, Non-Executive Chair | 03 Nov 2020 |
| NEW ROLE: Peter Marks, Non-Executive Director, Deputy Chair | 03 Nov 2020 |
| NEW ROLE: Boris Patkin, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: Graham Kelly, Non-Executive Director | 03 Nov 2020 |
| NEW ROLE: David Franks, Company Secretary | 03 Nov 2020 |
